↓ Skip to main content

Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients

Overview of attention for article published in Journal of Neuro-Oncology, November 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
77 Mendeley
Title
Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients
Published in
Journal of Neuro-Oncology, November 2015
DOI 10.1007/s11060-015-1987-7
Pubmed ID
Authors

Joanna Socha, Lucyna Kepka, Sunita Ghosh, Wilson Roa, Narendra Kumar, Valery Sinaika, Juliana Matiello, Darejan Lomidze, Douglas Guedes de Castro, Dalenda Hentati, Elena Fidarova

Abstract

Optimal treatment of recurrent glioblastoma multiforme (rGBM) in elderly and/or frail patients remains virtually unexplored, the best supportive care (BSC) only is routinely administered due to the fatal prognosis. We evaluated the impact of different treatment methods on post-progression survival (PPS) and overall survival (OS) of such patients. Data from 98 elderly and/or frail rGBM patients, treated initially with 1-week or 3-week radiotherapy (RT) within the phase III IAEA study (2010-2013), were analyzed. KPS at relapse and salvage treatment methods were recorded. Kaplan-Meier method was used to estimate PPS and OS for different treatment modalities. Eighty-four patients experienced recurrence: 47 (56 %) received BSC, 21 (25 %)-chemotherapy (CHT), 8 (9.5 %)-surgery, 3 (3.5 %)-RT, for 5 (6 %) the data was unavailable. Median OS from randomization for all 84 patients was 35 weeks: 55 versus 30 weeks for any treatment versus BSC, p < 0.0001. Median PPS was 15 weeks: 23 weeks with any treatment versus 9 weeks with BSC, p < 0.0001. For local treatment (surgery and/or RT) median PPS was 51 versus 21 weeks for CHT, p = 0.36. In patients with poor KPS (≤60) at relapse median PPS was 9 weeks with BSC versus 21 weeks with any treatment, p = 0.014. In poor KPS patients median PPS for local treatment was 14 weeks versus 21 weeks with CHT, p = 0.88. An active therapeutic approach may be beneficial for selected elderly and/or frail rGBM patients. Poor KPS patients may also benefit from active treatment, but there is no benefit of local treatment over CHT.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 1%
Unknown 76 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 14%
Student > Bachelor 9 12%
Student > Doctoral Student 7 9%
Student > Postgraduate 6 8%
Professor > Associate Professor 6 8%
Other 17 22%
Unknown 21 27%
Readers by discipline Count As %
Medicine and Dentistry 32 42%
Neuroscience 5 6%
Nursing and Health Professions 4 5%
Social Sciences 2 3%
Agricultural and Biological Sciences 2 3%
Other 7 9%
Unknown 25 32%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2018.
All research outputs
#6,963,891
of 22,836,570 outputs
Outputs from Journal of Neuro-Oncology
#914
of 2,971 outputs
Outputs of similar age
#88,425
of 285,422 outputs
Outputs of similar age from Journal of Neuro-Oncology
#14
of 67 outputs
Altmetric has tracked 22,836,570 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,971 research outputs from this source. They receive a mean Attention Score of 4.2. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 285,422 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.